Summary.-A group of 12 children with advanced neuroblastoma (7 Stage IV and 5 Stage III), selected by their initial response to chemotherapy with pulsed cyclophosphamide/vincristine/Adriamycin (CVA), were given consolidation therapy with high-dose melphalan (140 mg/M2) and then surgical removal of residual disease. Twenty-two high-dose melphalan procedures were combined with autologous marrow grafting to offset myelotoxicity and were well tolerated. In each of 2 additional children, procedures carried out without marrow autografting led to serious marrow and mucosal toxicity. There were no treatment-related deaths. In 7/11 patients with evaluable computerized tomographic (CT) scans there was a decrease in maximum diameter of the primary tumour after melphalan. Complete response was achieved in 6 patients, of whom 3 are well and have no evidence of disease at 35, 33 and 18 months from completion of all treatment; however, although survival (median 23 months) of all 12 autografted patients is longer than that of 28 comparable children treated between 1970-77 with conventional chemotherapy (median 14 months) the difference is not statistically significant. High-dose melphalan is a safe and tolarable treatment in children when combined with autologous marrow grafting, but further study is required to determine whether the procedure can improve prognosis for patients with advanced neuroblastoma.
ADVANCED NEUROBLASTOMA is one of the most lethal of all childhood neoplasms. The 2-year survival for children with Stage IV (Evans et al., 1971) disease (excluding IVs patients) diagnosed and treated by us with conventional chemotherapy, radiotherapy and surgery is 10-15% (Ninane et al., 1981) ; and this dismal experience is shared by others (Gasparini et al., 1974; Finklestein et al., 1979; Helson et al., 1979) . For stage III tumours, reported 2-year survival figures vary more, but in no series exceed 50 %; our own experience is that Stage III patients with unresectable primary disease fare just as badly as those with Stage IV disease (Ninane et al., 1981) .
Between 1977 and 1979 , in an attempt to improve the prognosis for children with advanced neuroblastoma, we studied the effect of high-dose melphalan (HDM) chemotherapy in 14 patients with Stage III or IV disease who had undergone "induction" chemotherapy with cyclophosphamide, vincristine and Adriamycin (CVA). We chose this approach because of previous experience of responses to HDM in patients with another neural-crest tumour, malignant melanoma (McElwain et al., 1979a) and because its major side-effect, myelotoxicity, could be overcome by autologous marrow grafting (McElwain et al., 1979b) . The short plasma half-life of melphalan permits the return of anticoagulated, non-cryopreserved marrow to the patient 8 h after harvesting (McElwain et al., 1979b) thus eliminating the technical problems of long-term marrow storage (Abrams et al., 1980) . A prerequisite for marrow autografting, carried our in 12 patients, was that the child's marrow was morphologically clear of tumour cells at the time of harvesting. Two patients, whose marrows still contained tumour cells despite CVA therapy, were also given HDM, but without marrow support.
In this paper, we assess the practicability and value of this treatment approach in 14 patients with advanced neuroblastoma. Some of our results have already been published in preliminary form (McElwain et al., 1979a Stage  III  IV  IV  IV  IV  IV  IV  III  III  III  IV  III  IV [Storring et al., 1977] or amphotericin/neomycin) were prescribed. Under general anaesthesia, a bladder catheter and a central venous line or Hickman catheter were inserted just before heparinization of the patient, and marrow was harvested as previously described for adults (McElwain et al., 1979a; Thomas et al., 1975) . One-2 ml marrow aspirates were taken into 20ml heparinized syringes from multiple sites in both anterior and posterior iliac crests and, in one case, the tibiae. Median yields of nucleated marrow cells were, for the first autograft, 41 x 108/kg (range 1-8-33-0 x 108) and, for the second, 4-6 x 108/kg (range 2-2-7-7 x 108/kg). Whole blood, equal in volume to that of the marrow aspirate, was transfused during the procedure. No protamine sulphate was given. The marrow was stored, at 4°C, in a plastic transfer pack. On return to the ward, patients were nursed in cubicles using a simple "reverse isolation" technique with hand-washing and gowning. One parent "lived in" with each child and carried out many of the simpler nursing procedures. After recovery from anaesthesia, a few patients required a single dose of morphine for discomfort from sites of marrow aspiration. Melphalan (140 mg/i.v. as bolus) was given through the central venous line 1-2 h after recovery from anaesthesia; a brisk diuresis (6-8 ml urine/kg/h) was then induced using frusemide (2 mg/kg) and normal saline with added potassium. Eight hours after melphalan the marrow was returned via the central venous line. Twenty-four hours after melphalan, the bladder catheter was removed and the diuresis discontinued, but most children required i.v. fluids for a further 24-48 h because of nausea and anorexia.
Appropriate supportive care was given during the 2-3 weeks of pancytopenia following HDM. After 4-6 weeks at home and recovery of their blood count, 10 patients returned to hospital for a second HDM procedure. Patient 8 declined further chemotherapy and abnormal liver function tests post-HDM were considered a contra-indication to a second procedure in patient 4.
Further treatment and follow-up.-No further chemotherapy was given, but, 6-10 weeks after HDM, 9 patients underwent exploratory leparotomy in an attempt to remove residual disease or, at least, obtain samples for histology. Radiotherapy was given to 2 patients with localized residual abdominal disease after surgery: patient 9 received a dose (25 Gy in 10 fractions over 29 days) considered technically and therapeutically adequate, but in patient 10 a final dose of 15 Gy (considered suboptimal) was achieved only after several interruptions because of thrombocytopenia.
All treatment was concluded between 9 and 15 months (median 12) from diagnosis.
Subsequent follow-up was with regular clinical examination and VMA estimations, 4-monthly marrow examinations and abdominal ultrasound and bone scans or skeletal surveys when indicated.
RESULTS OF TREATMENT
Tumour response (Table II) Of the 12 patients who, just before HDM, had localized disease only, 11 had evaluable serial CT scans, and 7 showed some shrinkage of maximum tumour diameter as a result of the treatment (e.g. Fig. 2 ) "Complete response" (CR) status (defined as: no clinical or imaging evidence of primary or secondary tumour, normal marrow aspirates and/or trephines and normal urinary VMA) was achieved in 6 of these 12 patients, but in patients 1, 2, 5 and 11, only after surgical excision of residual disease. Six children never All children received platelet support at counts below 20 x 109/1; only one instance of overt bleeding was detected, and responded promptly to further platelet transfusion. After 2 courses of HDM, 3 patients, each of whom ultimately succumbed to tumour, had persistent thrombocytopenia stabilizing at 50-100 x 109/1 (see Fig. 4 ).
Since total nucleated cell yields and marrow volumes were similar for both harvests in the 10 patients who underwent 2 autografts, this incomplete haemopoietic reconstitution was not apparently related to a reduced marrow "dose" at the second procedure. The 2 patients without autografts showed slower blood-count recovery than the grafted patients; consequently, they spent longer in hospital (median PHA and loss of skin reactivity to candidin just after HDM. Unfortunately, neither patient survived long enough to permit retesting at a longer interval after melphalan. Serious viral or fungal infections, however, did not occur; one child developed shingles and another measles 22 months after their last chemotherapy but recovered without complications.
Other complications of treatment were rare. One patient developed hyperuricaemia (1 1 mM) 3 days after his first HDM treatment; since this episode coincided with a rapid decrease in size of the primary tumour, it was presumed to be the consequence of cell lysis, a phenomenon we have never encountered in children with neuroblastoma receiving conventional chemotherapy. Serial electrolyte estimations after HDM were normal, as were liver-function tests, except in one child whose SGOT and SGPT were moderately raised, without jaundice, for 6-8 weeks. Most children lost > 10% of their body weight as a result of each HDM treatment but quickly regained it after discharge from hospital and before a second procedure.
DISCUSSION
In designing this protocol we had in mind the characteristics of relapse in patients with Stage III and IV neuroblastoma. After partial response to conventional treatment, "recurrence" is generally local within a median time of about 6 months, whilst after CR tumour recurrence characteristically occurs at metastatic sites after a median of 15 months (Ninane et al., 1981) . Surgical resection of disease after conventional chemotherapy, with or without radiotherapy, does not appear to improve survival (Finklestein et al., 1979) . Sequential segmental whole-body irradiation did not improve duration of first response in one reported series (Green et al., 1976) and although single-dose 10 Gy total-body irradiation followed by allogeneic marrow grafting from an HL-A compatible sibling requires further investigation, early results are not encouraging (Klemperer et (Thurman et al., 1964) lack predictable dose-related specific organ toxicity. We decided against the use of cyclophosphamide because of (a) the risk of cystitis (Phillips et al., 1961) and cardiomyopathy (Buchner et al., 1972) , (b) the need, after CVA induction therapy, to expose the tumours to a "new" agent in order to side-step the problem of emerging drug resistance and (c) the reported failure of high-dose cyclophosphamide to improve the prognosis in advanced neuroblastoma (Helson, 1979; Nitschke et al., 1979a) . Encouraged by response rates to Peptichemio (de Bernardi et al., 1978) up to 9200, we decided to use the closely related alkylating agent melphalan for high-dose consolidation. The only previous use of melphalan in neuroblastoma was not encouraging, but in that study (Fernbach et al., 1968) and in contrast to our own plans, a low-dose schedule of oral administration was used. Our protocol was so designed that HDM would be introduced at a time of estimated minimum tumour burden; we measured its effect by serial CT scanning, laparotomy after treatment and crude survival.
Marrow harvesting, even in the smallest children, presented no particular problems, though in one 2-year-old tibial marrow was aspirated to reach an adequate cell dose. Of considerable importance was the fact that none of these children had previously received pelvic irradiation, which greatly reduces the chance of an adequate cell yield. The mean dose was similar to that used in adults (McElwain et al., 1979a) . HDM was well tolerated in all patients who received autologous marrow grafts. No lifethreatening episodes, apart from one septicaemia, were encountered in the entire series, but our experience of serious complications with the 2 non-autografted children, their marrows admittedly compromised by tumour infiltration, together with our previous findings in adults (McElwain et al., 1979b) convince us that marrow autografting significantly reduces the morbidity from HDM therapy. Oral non-absorbable antibiotics and nystatin were administered, but compliance was poor because of mucositis and nausea. We now use the more palatable combination of Cotrimoxazole and nystatin for patients undergoing HDM therapy. Energetic diuresis was used after melphalan, because 2 adult patients, early in our experience (McElwain et al., 1979a) developed compromised renal function post-HDM. We now have evidence that diuresis is unnecessary.
Weight loss of > 10% in each of our patients might have been prevented by early i.v. feeding: we now invariably start parenteral feeding immediately after HDM.
The 14 children reported here represent less than two-thirds of the 22 patients referred to our 3 hospitals with a diagnosis of Stage III or IV neuroblastoma during the 2 years of the study. Of the remainder, 6 were considered ineligible for HDM because of non-response to initial (CVA) chemotherapy, 1 because of pre-existing brain damage, and the last because of a chemotherapy-induced malabsorption syndrome. That our patients are a "selected" group thus primarily reflects the failure of CVA as an induction regimen.
Three children (Stage III patients 1 and 12, Stage IV patient 2) are well and free of evidence of disease between 11-3 years from the end of treatment. The survival of the 12 patients who had localized disease just before :HDM (median 23 months) is, however, not significantly different (Logrank test P = 0 76) from that of previous patients achieving clinical CR by conventional therapy (median 14 months- Ninane et al., 1981) . Moreover, neither child with overt metastases at the time of HDM showed objective response to the treatment. However, since all therapy was completed 9-15 months after diagnosis, the quality of the subsequent lives of children receiving HDM was substantially better than those treated prior to 1977.
In 8/9 relapsing patients, disease returned at metastatic sites; however, there was simultaneous local recurrence in 3 of these children, each of whom had had incomplete surgical resection, and one had a suboptimal radiation dose as well. We therefore feel that a more aggressive approach towards residual localized disease, using both surgery and high-dose ageadjusted radiation therapy, even in the face of a falling blood count, would have been justified. There are several possible explanations for relapse at distant sites. The most likely is that HDM failed to destroy occult metastases; alternatively, the "new" metastases might represent re-seeding of tumour cells either present in the reinfused autologous marrow or from the primary site. The pattern and timing of reappearance of metastases does not permit distinction between these possibilities, of which the third seems unlikely in the 5 cases in which secondary disease recurred without evidence of local relapse.
We conclude that HDM is a safe and tolerable procedure in children when combined with autologous marrowgrafting, expert nursing and close parental support in specialized units. Because of encouraging results of high-dose chemotherapy, including melphalan, in other forms of cancer (Ziegler et al., 1977 , Cornbleet et al., 1981 and despite the disappointing overall results in this series of children, we continue to use HDM consolidation in patients with advanced neuroblastoma. We now use more intensive induction therapy, including cis-Platinum and VM-26, agents which have been shown to be active both individually (Rivera et al., 1977 , Nitschke et al., 1979b and together (Hayes et al., 1981) in neuroblastoma, and pay particular attention to the radiation and surgical therapy of residual primary disease. Finally, we are exploring the possibility that monoclonal antibodies, known to bind to human neuroblastoma cells (Kemshead et al., 1981) might be used to "clean up" autologous marrow before reinfusion.
